Single Asset Sends Ceptaris into Actelion's Arms
By Marie Powers
Thursday, August 1, 2013
Ceptaris Therapeutics Inc. found a home for its single asset, Valchlor (mechlorethamine gel), with Actelion U.S. Holdings Co., a subsidiary of Swiss drugmaker Actelion Ltd. But there's a catch: The $250 million deal is contingent upon FDA approval of the product.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.